To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination

被引:94
作者
Chiu, Nan-Chang [1 ,2 ]
Chi, Hsin [1 ,2 ]
Tu, Yu-Kang [3 ]
Huang, Ya-Ning [1 ]
Tai, Yu-Lin [4 ]
Weng, Shun-Long [5 ]
Chang, Lung [2 ,6 ]
Huang, Daniel Tsung-Ning [1 ,2 ]
Huang, Fu-Yuan [1 ]
Lin, Chien-Yu [2 ,4 ]
机构
[1] MacKay Childrens Hosp, Dept Pediat, Taipei, Taiwan
[2] MacKay Med Coll, Dept Med, New Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol & Prevent Med, Taipei, Taiwan
[4] Hsinchu MacKay Mem Hosp, Dept Pediat, Hsinchu, Taiwan
[5] Hsinchu MacKay Mem Hosp, Dept Obster & Genecol, Hsinchu, Taiwan
[6] Tamshui MacKay Mem Hosp, Dept Pediat, New Taipei, Taiwan
关键词
COVID-19; Sars-COV-2; vaccination; heterologous; boost; chadox1; mRNA; EFFICACY; VACCINES;
D O I
10.1080/14760584.2021.1971522
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Coronavirus disease 2019 (COVID-19) has had an enormous impact worldwide, and vaccination is believed to be the method that will control the pandemic. Several types of vaccines developed using different platforms have been authorized, but the immunogenicity and reactogenicity of heterologous prime-boost vaccination with different vaccines remain largely unclear. Areas covered Electronic databases including PubMed, Embase, medRxiv, Research Square, and SSRN were searched to investigate the immunogenicity and reactogenicity associated with heterologous vaccination. As of 30 June 2021, four trials including 1,862 participants were identified. Heterologous administration of BNT162b2 (BNT) in ChAdOx1 (ChAd)-primed participants (ChAd/BNT) showed noninferior immunogenicity to homologous BNT administration (both prime and booster were BNT vaccines, BNT/BNT) with tolerable reactogenicity and higher T cell responses. Compared with homologous ChAdOX1 vaccination (ChAd/ChAd), heterologous ChAd/BNT was found to elicit higher immunogenicity (ChAd/BNT vs. ChAd/ChAd, antibody titer ratio: 9.2). Expert opinion Our systematic review found robust immunogenicity and tolerable reactogenicity of heterologous administration of a BNT162b2 boost in ChAdOx1-primed participants. An additional benefit of stronger T cellular immunity was also observed. Heterologous vaccination is a reasonable and feasible strategy to combat COVID-19. Further studies are warranted to confirm the benefits and identify the optimal combinations, doses, and intervals.
引用
收藏
页码:1211 / 1220
页数:10
相关论文
共 49 条
[1]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[2]   Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses [J].
Barrett, Jordan R. ;
Belij-Rammerstorfer, Sandra ;
Dold, Christina ;
Ewer, Katie J. ;
Folegatti, Pedro M. ;
Gilbride, Ciaran ;
Halkerston, Rachel ;
Hill, Jennifer ;
Jenkin, Daniel ;
Stockdale, Lisa ;
Verheul, Marije K. ;
Aley, Parvinder K. ;
Angus, Brian ;
Bellamy, Duncan ;
Berrie, Eleanor ;
Bibi, Sagida ;
Bittaye, Mustapha ;
Carroll, Miles W. ;
Cavell, Breeze ;
Clutterbuck, Elizabeth A. ;
Edwards, Nick ;
Flaxman, Amy ;
Fuskova, Michelle ;
Gorringe, Andrew ;
Hallis, Bassam ;
Kerridge, Simon ;
Lawrie, Alison M. ;
Linder, Aline ;
Liu, Xinxue ;
Madhavan, Meera ;
Makinson, Rebecca ;
Mellors, Jack ;
Minassian, Angela ;
Moore, Maria ;
Mujadidi, Yama ;
Plested, Emma ;
Poulton, Ian ;
Ramasamy, Maheshi N. ;
Robinson, Hannah ;
Rollier, Christine S. ;
Song, Rinn ;
Snape, Matthew D. ;
Tarrant, Richard ;
Taylor, Stephen ;
Thomas, Kelly M. ;
Voysey, Merryn ;
Watson, Marion E. E. ;
Wright, Daniel ;
Douglas, Alexander D. ;
Green, Catherine M. .
NATURE MEDICINE, 2021, 27 (02) :279-+
[3]   Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination [J].
Barros-Martins, Joana ;
Hammerschmidt, Swantje, I ;
Cossmann, Anne ;
Odak, Ivan ;
Stankov, Metodi, V ;
Ramos, Gema Morillas ;
Dopfer-Jablonka, Alexandra ;
Heidemann, Annika ;
Ritter, Christiane ;
Friedrichsen, Michaela ;
Schultze-Florey, Christian ;
Ravens, Inga ;
Willenzon, Stefanie ;
Bubke, Anja ;
Ristenpart, Jasmin ;
Janssen, Anika ;
Ssebyatika, George ;
Bernhardt, Gunter ;
Muench, Jan ;
Hoffmann, Markus ;
Poehlmann, Stefan ;
Krey, Thomas ;
Bosnjak, Berislav ;
Foerster, Reinhold ;
Behrens, Georg M. N. .
NATURE MEDICINE, 2021, 27 (09) :1525-+
[4]   Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant [J].
Bernal, Jamie Lopez ;
Andrews, Nick ;
Gower, Charlotte ;
Gallagher, Eileen ;
Simmons, Ruth ;
Thelwall, Simon ;
Stowe, Julia ;
Tessier, Elise ;
Groves, Natalie ;
Dabrera, Gavin ;
Myers, Richard ;
Campbell, Colin N. J. ;
Amirthalingam, Gayatri ;
Edmunds, Matt ;
Zambon, Maria ;
Brown, Kevin E. ;
Hopkins, Susan ;
Chand, Meera ;
Ramsay, Mary .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) :585-594
[5]   Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies [J].
Bian, Lianlian ;
Gao, Fan ;
Zhang, Jialu ;
He, Qian ;
Mao, Qunying ;
Xu, Miao ;
Liang, Zhenglun .
EXPERT REVIEW OF VACCINES, 2021, 20 (04) :365-373
[6]   Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial [J].
Borobia, Alberto M. ;
Carcas, Antonio J. ;
Perez-Olmeda, Mayte ;
Castano, Luis ;
Jesus Bertran, Maria ;
Garcia-Perez, Javier ;
Campins, Magdalena ;
Portoles, Antonio ;
Gonzalez-Perez, Maria ;
Garcia Morales, Maria Teresa ;
Arana-Arri, Eunate ;
Aldea, Marta ;
Diez-Fuertes, Francisco ;
Fuentes, Inmaculada ;
Ascaso, Ana ;
Lora, David ;
Imaz-Ayo, Natale ;
Baron-Mira, Lourdes E. ;
Agusti, Antonia ;
Perez-Ingidua, Carla ;
Gomez de la Camara, Agustin ;
Ramon Arribas, Jose ;
Ochando, Jordi ;
Alcami, Jose ;
Belda-Iniesta, Cristobal ;
Frias, Jesus .
LANCET, 2021, 398 (10295) :121-130
[7]  
Chaimani A, 2017, EVID-BASED MENT HEAL, V20, P88, DOI 10.1136/eb-2017-102753
[8]   Taiwan Government-Guided Strategies Contributed to Combating and Controlling COVID-19 Pandemic [J].
Chen, Chung-Chu ;
Tseng, Cheng-Yin ;
Choi, Wai-Mau ;
Lee, Ya-Chun ;
Su, Tsung-Hsien ;
Hsieh, Chin-Yi ;
Chang, Chih-Ming ;
Weng, Shun-Long ;
Liu, Po-Huang ;
Tai, Yu-Lin ;
Lin, Chien-Yu .
FRONTIERS IN PUBLIC HEALTH, 2020, 8
[9]   Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination [J].
Chen, Yuxin ;
Zhu, Liguo ;
Huang, Weijin ;
Tong, Xin ;
Wu, Hai ;
Tao, Yue ;
Tong, Bei ;
Huang, Haibin ;
Chen, Jiachen ;
Zhao, Xiangan ;
Lou, Yang ;
Wu, Chao .
EMERGING MICROBES & INFECTIONS, 2021, 10 (01) :1390-1403
[10]   Clinical features of neonates born to mothers with coronavirus disease-2019: A systematic review of 105 neonates [J].
Chi, Hsin ;
Chiu, Nan-Chang ;
Tai, Yu-Lin ;
Chang, Hung-Yang ;
Lin, Chao-Hsu ;
Sung, Yi-Hsiang ;
Tseng, Cheng-Yin ;
Liu, Lawrence Yu-Min ;
Lin, Chien-Yu .
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2021, 54 (01) :69-76